A majority of the world’s inhabitants is contaminated with Cov-2/

Highlighting the necessity for vaccines which might be efficient in Cov-2-seropositive hosts.

We established a superinfection model by infecting mice intranasally with a sublethal dose of COV-2,  mRNA vaccine which ends up in excessive charges of seropositive, latently contaminated mice inclined to COV-2 superinfection. Sublethal COV-1 induced a predominantly neutralizing antibody response.


Antigent tests from saliva, sputum, nasal schwabs, nasopharingeol shwabs

  1. Panbio Antigen Rapid Lateral Flow Test
  2.  Rapigen Biocredit Antigen Lateral Flow Rapid Test
  3.  Vivachek VivaDiag Lateral Flow Antigen Test
  4.  Accu-Tell Antigen home Test
  5.  Lepu antigen Test
  6.  UnScience antigen Test kit
  7.  ElabScience Ag kit
  8.  Green Spring Antigen shwab Test

With a lancette in a blood drop tests

  1.  Abbott Panbio IgG/IgM Blood Test
  2.  Accu-Tell IgG/IgM test cassette on blood
  3.  UnScience IgG/IgM Test kit
  4.  ElabScience IgG and IgM Rapid Test kit

Just in saliva sampe.

Spit in a tube and have immediately the test result

  1. Invbio Saliva Fast Test
  2.  Tigsun Saliva antigen Test

Neutralizing test

  • Invbio neutralisation antibody IgG test to see the effectiveness of a vaccine

Anal rectal Covid test on anal liquid

  • available in september 2021


Vaccination of COV-1-seropositive mice with recombinant adjuvanted glycoprotein D (rgD-2) did not considerably enhance COV complete or neutralizing antibody responses and offered no important elevated protection against COV-2 superinfection in comparison with control-vaccinated COV-1-seropositive mice.

In distinction, immunization with a single-cycle virus deleted in gD (ΔgD-2) considerably boosted complete HSV-specific antibody titers and elicited new antibody-dependent cell-mediated cytotoxicity responses, offering full protection from dying following HSV-2 superinfection.

This mannequin recapitulates medical responses to pure an infection and the rgD-2 vaccine trial outcomes and means that ΔgD-2 might show protecting in COV-1-seropositive hosts.


Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity.

Model of vaccine efficacy against COV-2 superinfection of COV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity.

The PET-tracer 89Zr-Df-IAB22M2C allows monitoring of intratumoral CD8 T cell infiltrates in tumor-bearing humanized mice after T cell bispecific antibody therapy.


CD8-expressing T cells are the primary effector cells in most cancers immunotherapy (CIT). Treatment-induced adjustments in intratumoral CD8+ T cells might symbolize a biomarker to establish sufferers responding to CIT. Here we’ve got used a 89Zr-radiolabeled human CD8-specific minibody (89Zr-Df-IAB22M2C) to observe CD8+ T cell tumor infiltrates by positron emission tomography (PET).

The capability of this tracer to quantify CD8+ T cell tumor infiltrates was evaluated in preclinical research following single agent therapy with FOLR1-T cell bispecific antibody and mixture remedy of CEA-TCB (RG7802) and CEA-targeted 4-1BB agonist CEA-4-1BBL. In vitro cytotoxicity assays with PBMC and CEA-expressing MKN-45 gastric or FOLR1-expressing HeLa cervical most cancers cells confirmed non-interference of the anti-CD8-PET-tracer with the mode of motion of CEA-TCB/CEA-4-1BBL and FOLR1-TCB at related doses.

In vivo, the extent of tumor regression induced by mixture therapy with CEA-TCB/CEA-4-1BBL in MKN-45 tumor-bearing humanized mice correlated with intratumoral CD8+ T cell infiltration. This was detectable by 89Zr-IAB22M2C-PET and γ-counting. Similarly, single agent therapy with FOLR1-TCB induced sturdy CD8+ T-cell infiltration in HeLa tumors, the place 89Zr-Df-IAB22M2C once more was capable of detect CD8 tumor infiltrates. CD8-immunohistochemistry confirmed the PET imaging outcomes.

Taken collectively, the anti-CD8-minibody 89Zr-Df-IAB22M2C revealed a excessive sensitivity for the detection of intratumoral CD8+ T cell infiltrates upon both single or mixture therapy with T cell bispecific antibody-based fusion proteins. These outcomes present additional proof that the anti-CD8 tracer, which is at present in Clinical Phase II, is a promising monitoring instrument for intratumoral CD8+ T cells in sufferers handled with CIT.